Naslov
Allogeneic BMT for acute lymphoblastic leukemia in adults - long term survival

Autori
Mrsić, Mirando ; Labar, Boris ; Bogdanić, Vinko ; Nemet, Damir ; Radman, Ivo ; Metelko-Kovačević, Jasminka ; Aurer, Igor ; Šalek-Zupančić, Silva ; Sertić, Dubravka ; Pisk, Mirta

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Bone Marrow Transplantation / Goldman J.M. - London : Delhi : Stockton, 1998, 6-6

Skup
24th Annual Meeting European Group for Blood and Marrow Transplantation

Mjesto i datum
Courmayeur, Italija, 22.03.1998. - 26.03.1998

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
allogeneic BMT; acute lymphoblastic leukemia

Sažetak
From October 1984 to March 199, 64 patients with acute lymphoblastic leukemia in first or second complete remission received allogeneic bone marrow from therir HLA-identical sibling. Median age was 28 (range 18-49 years). Patients were conditioned with cyclophosphamide 120 mg/kg and total body irradiation (TBI), 12 Gy, at a dose rate of 2.9-5.7 cGy/min in a three 4Gy fractions given daily over 3 days. For GVHD prophylaxis patients received cyclosporine alone or standard short methotrexate and cyclosporine. Amedian of 2.1 (range 1.2-5.2) x 10E8/kg of marrow cells were infused. The median follow-up period is 85 months (range 6-150). Overall probability of LFS is 35% at 60 months. Patients allografted in first CR had better LFS 52% compared to the patients treated in second CR, 30% (p<0.05). Acute GVHD grade II-IV was documented in 29 (48%) patients while chronic GVHD was diagnosed in 21 (42%) patients. The overall probability of TRM for ALL is 26% at 60 months. There was no any influence of the disease stage on TRM. Relapse was the main cause of ddeath in both groups.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA